Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial

Published:2012-05 Issue:5 Volume:28 Page:437-446
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Wilkin Aimee¹,Pozniak Anton L.²,Morales-Ramirez Javier³,Lupo Sergio H.⁴,Santoscoy Mario⁵,Grinsztejn Beatriz⁶,Ruxrungtham Kiat⁷,Rimsky Laurence T.⁸,Vanveggel Simon⁸,Boven, on behalf of the TMC278-C204 Katia⁹

Affiliation:

1. Wake Forest University Health Sciences, Winston-Salem, North Carolina.

2. Chelsea and Westminster NHS Foundation Trust and PKR/SSR, London, United Kingdom.

3. Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico.

4. Universidad Nacional de Rosario, Santa Fe, Argentina.

5. Hospital Carlos Mac Gregor IMSS, Mexico City, Mexico.

6. Instituto de Pesquisa Clínica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil.

7. HIV-NAT, Thai Red Cross AIDS Research Centre and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

8. Tibotec BVBA, Beerse, Belgium.

9. Tibotec Inc., Titusville, New Jersey.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2011.0050

Reference11 articles.

1. The first once-daily single-tablet regimen for the treatment of HIV-infected patients

2. TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

3. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

4. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

5. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous Estiamtion of Dolutegravir and Rilpivirine and Their Impurities using RP-HPLC;Oriental Journal Of Chemistry;2024-02-25

2. Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies;Antiviral Therapy;2021-11

3. Effect of the anti-retroviral drug, rilpivirine, on human subcutaneous adipose cells and its nutritional management using quercetin;Molecular and Cellular Biochemistry;2020-06-13

4. Current structure-based methods for designing non-nucleoside reverse transcriptase inhibitors;Future Virology;2019-08

5. The role of rilpivirine in Southern Africa;Southern African Journal of HIV Medicine;2019-05-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3